

## **COVID-19: Yet Another Coronavirus Challenge in Transplantation**

Saima Aslam, MD, MS<sup>1</sup>, Mandeep R Mehra, MD, MSc<sup>2</sup>

<sup>1</sup>Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA; Center for Advanced Heart Disease, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

**Corresponding Author:** Mandeep R. Mehra, Center for Advanced Heart Disease, 75 Francis Street, Boston, MA 02115 or at [MMEHRA@BWH.HARVARD.EDU](mailto:MMEHRA@BWH.HARVARD.EDU)

Fax: 617-264-5265; Tel: 617-732-8534; Twitter Handle: @MRMehraMD

A novel coronavirus, SARS-CoV-2, causing a severe acute respiratory syndrome with its disease designated as COVID-19, emerged from its epicenter in Wuhan China in December 2019 and is now a global pandemic. As of March 11<sup>th</sup> 2020, COVID -19 has been confirmed in 114 countries, involves 118,381 cases globally with 4292 deaths.(1) The majority of reported infections are in China followed by Italy, Iran, Republic of Korea and the European Union.(1) Italy has gone into lockdown as a country on March 9, 2020, while in other countries such as the United States of America, several states have declared emergencies, focal biocontainment territories have been placed on lockdown and cases are being reported to increase at an alarming rate.(2) The rapid increase is owed to the fact that more widespread testing is now slowly becoming available however, this virus uniquely is more efficient in its rate of transmissibility with an individual capable of spreading to 1-3 others.(3) The presentation of illness mimics that of a flu like illness with fever and respiratory symptoms as common presenting complaints and bilateral patchy infiltration is typically noted on computed tomography (CT) scans.(4) The majority of COVID-19 cases (87%) occur between 30-79 years of age and most (81%) are mild. The remaining 14% present with severe symptoms while 5% require care in an intensive care unit (ICU).(5) The case-fatality rate has been touted to be 2.3% overall (although this is likely overestimated due to the lack of wide spread testing), however death rates climb in those aged  $\geq 80$  years (15%) and in nearly half of those requiring critical care.(5) Those with cancer receiving chemotherapy as well as patients with multiple co-morbidities are distinctively at a higher risk for severe illness.(5, 6) However, information on the predilection, presentation and prognosis of COVID-19 in solid organ transplantation is sparse and has not been adequately reported.

In this issue of the *Journal*, Li and colleagues (7) report on the presentation and outcome of two microbiologically confirmed COVID-19 cases in heart transplantation detected in the Hubei province in China. These two patients apparently were part of a community of at least 200 heart transplant survivors in that region and presented with variable severity of disease (one mild and another with more severe manifestations requiring a prolonged hospitalization) however both survived the event. It is important to note that the clinical

presentations were not distinct from those described in non-immunosuppressed individuals and the patient with severe disease presented with a viral prodrome, displayed the typical findings on CT scan imaging and progressed to clinical hypoxia. The second patient presented with a fever and mild CT scan findings (this being the screening modality used in China) with resolution in a few days. The laboratory findings mirrored those observed in non-transplant patients with elevated C-Reactive Protein levels and lymphopenia. The treatment for the patient with severe disease included withholding baseline immunosuppression and treating with high dose corticosteroids and pooled immunoglobulin infusions. A “kitchen-sink” approach to the cases also included the use of a fluoroquinolone along with ganciclovir, but whether this therapy was useful cannot be determined by this limited reporting. Crucially, the patient recovered to discharge without incurring immunological consequences on the cardiac allograft and remained rejection-free.

Whether transplantation related immunosuppression alters the predisposition to acquiring infection with SARS-CoV-2 or if the disease implications are modified for better or for worse remain uncertain. The novel coronavirus achieves its anchoring to the lung by using the Angiotensin Converting Enzyme (ACE)-2 receptor. The pulmonary renin-angiotensin-aldosterone system via ACE-2 has been implicated in prevention of lung inflammation.<sup>(8)</sup> When this system is overpowered by SARS-CoV-2, pulmonary inflammatory infiltrates emerge expressing the COVID-19 disease phenotype. It is unknown if heart transplant recipients have differential expression of pulmonary ACE-2 since a lower expression may result in less severe illness. Similarly, the anti-inflammatory effects of immunosuppression could diminish the clinical expression of disease as well. These speculative assumptions will require structured studies to enhance our understanding of this disease pathway and processes.

It is however likely that immunosuppressed patients may be prone to acquiring the virus at higher risk due to its high efficiency in transmission. The virus shedding has been noted not only in respiratory specimens but also in serum and stool. Importantly, viral shedding can occur for days for weeks furtively in asymptomatic

carrier individuals especially children (3,9,10) and fecal shedding has been noted in patients without diarrhea.(10) Significant environmental contamination has been noted, including wash-basin, toilet bowl and air outlet fan surfaces in hospitalized patients.(11) Thus, it is prudent to advise transplant recipients to ardently practice mitigation strategies such as social distancing, sanitization, hand hygiene and avoidance of areas known to harbor potentially infected individuals. These recommendations extend to their care providers as well.

Therapy for manifest disease is gravely lacking at this time although promise is on the horizon. While several molecules are under investigation, Remdesivir (an adenosine analogue that incorporates into viral RNA chains and results in premature termination) and Chloroquine (an anti-malarial drug that increases prevents viral cell fusion, and interferes with glycosylation of cellular receptors of SARS-CoV) appear to have early in-vitro evidence in support of their potential activity against SARS-CoV-2.(12,13) Other drugs, such as ribavirin, interferon, lopinavir-ritonavir and corticosteroids that have been used in patients with the 2003 SARS or the 2012 Middle Eastern Respiratory Syndrome (MERS), are candidates for investigation. The reason is that the novel corona virus belongs to the *Betacoronavirus* family which also contains SARS-CoV and Middle East respiratory syndrome CoV (MERS-CoV).(12) Hyperimmune globulin that contains targeted antibodies against SARS-CoV-2, derived from the plasma of recovered individuals and thus capable of providing passive immunity, may also be therapeutic.(14) Ultimately, control of this outbreak will require the development of a vaccine. An important area of significant concern to transplant clinicians will involve the testing of donors, decisions on organ suitability from those recently exposed or infected and the implications of recovery of such organs by procurement teams. This will need to be debated and studied rapidly as more widespread testing becomes available. At this time, it would be prudent to avoid transplanting organs from donors with a history of contact with someone at risk or diagnosed with COVID-19 as well as those with recent travel to an area with high density of infection.

In summary, the novel corona virus and its disease, COVID-19 requires thoughtful approaches for the prevention, mitigation, timely detection and appropriate therapeutic intervention for our vulnerable patients.

**Disclosures:** Dr. Aslam reports consulting fees from Merck, unrelated to this manuscript; Dr. Mehra reports no direct conflicts pertinent to the development of this editorial. Other general conflicts include consulting relationships with Abbott, Medtronic, Janssen, Mesoblast, Portola, Bayer, NupulseCV, FineHeart, Leviticus and Triple Gene. Dr. Mehra is also Editor in Chief of the Journal of Heart and Lung Transplantation and should be considered to be the personal opinion of the authors and not the official stance of the ISHLT.

## References:

1. WHO: Rolling Updates on Coronavirus Disease (COVID-19). <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen>. Accessed March 11, 2020
2. Centers for Disease Control and Prevention: Coronavirus Disease 2019 (COVID-19) in the U.S. <https://www.cdc.gov/coronavirus/2019-ncov/cases-in-us.html>. Accessed March 11 2020
3. Li Q, Guan X, Wu P, et al.: Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *New England Journal of Medicine* 2020. Jan 29. doi: 10.1056/NEJMoa2001316
4. Guan WJ, Ni ZY, Hu Y, et al.: Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020. February 28. DOI: 10.1056/NEJMoa2002032
5. Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA* 2020. February 24. doi:10.1001/jama.2020.2648
6. Liang W, Guan W, Chen R, et al.: Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020;21:335-7.
7. Li F, Cai J, Dong N. First Cases of COVID-19 in Heart Transplantation From China, *JHLT* 2020 (Please Update)
8. Tikellis C, Thomas MC. Angiotensin-Converting Enzyme 2 (ACE2) Is a Key Modulator of the Renin Angiotensin System in Health and Disease. *Int J Pept*.2012;2012:256294. doi: 10.1155/2012/256294. Epub 2012 Mar 20.
9. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, Ma H, Chen W, Lin Y, Zheng Y, Wang J, Hu Z, Yi Y, Shen H. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci*.2020 Mar 4. doi: 10.1007/s11427-020-1661-4.
10. Kai-qian Kam CFY, Lin Cui, Raymond Lin Tzer Pin, Tze Minn Mak, Matthias Maiwald, Jiahui Li, Chia Yin Chong, Karen Nadua, Natalie Woon Hui Tan, Koh Cheng Thoon: A Well Infant with Coronavirus Disease 2019 (COVID-19) with High Viral Load. *Clinical Infectious Diseases* 2020 Feb 28. pii: ciaa201. doi: 10.1093/cid/ciaa201.
11. Ong SWX, Tan YK, Chia PY, et al.: Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *JAMA* 2020. March 4. doi:10.1001/jama.2020.3227
12. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). *Drug Discov Ther*. 2020;14(1):58-60.
13. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 2020 Mar;30(3):269-271.
14. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw FM, Lim WS, Makki S, Rooney KD, Nguyen-Van-Tam JS, Beck CR; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis*. 2015 Jan 1;211(1):80-90.